1. Academic Validation
  2. Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy

Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy

  • J Leukoc Biol. 2022 Aug;112(2):299-311. doi: 10.1002/JLB.6A0821-409RR.
Ruolan You 1 Diyu Hou 1 Bin Wang 1 Jingru Liu 1 Xiaoting Wang 1 Qirong Xiao 2 Zhipeng Pan 1 Dongliang Li 3 Xiaoming Feng 4 Lixia Kang 1 Ping Chen 2 Huifang Huang 1
Affiliations

Affiliations

  • 1 Central Laboratory, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
  • 2 Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
  • 3 Department of Hepatobiliary Disease, The 900th Hospital of the People's Liberation Army Joint Service Support Force, Fuzhou, Fujian, China.
  • 4 State Key Laboratory of Experimental Hematology, Institute of Hematology and Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Abstract

The stromal niche plays a pivotal role in AML chemoresistance and energy metabolism reprogramming is a hallmark of a tumor. 5'-Adenosine monophosphate-activated protein kinase (AMPK) is an important energy sensor suppressing mammalian target of rapamycin complex 1 (mTORC1) activity. However, the role of AMPK-mTORC1 pathway on connecting AML cell energy metabolism reprogramming and chemoresistance induced by the bone marrow microenvironment (BMM) is not defined. Here, with a co-culture system that simulates the interaction between BMM and AML cells, it is shown that stromal contact led to a decreased sensitivity to chemotherapy accompanied by an increase of Oxidative Phosphorylation (OXPHOS) activity and mitochondrial ATP synthesis in AML cells. The increased OXPHOS activity and excessive ATP production promoted chemoresistance of AML cells through inhibiting AMPK activity and in turn activating mTORC1 activity. In an in vivo AML mouse model, depletion of AMPK activity with genetic targeting promoted AML progression and reduced their sensitivity to chemotherapeutic drugs. Collectively, AML cells' acquired increased OXPHOS activity as well as AMPK inhibition could be therapeutically exploited in an effort to overcome BMM-mediated chemoresistance.

Keywords

AMPK-mTORC1 pathway; ATP; OXPHOS; acute myeloid leukemia; chemotherapy resistance.

Figures
Products